# Probiotics: Strains, Clinical Effects, and Safety

- Canonical: https://nutrifit.health/knowledge/probiotics-gut-microbiome-safety
- Language: en
- Published: 2026-09-02T00:50:48.267Z
- Updated: 2026-10-02T18:35:16.119Z
- Author: NutriFit Editorial

> Probiotics are chosen based on specific strains, composition, dosage, and clinical objectives. We analyze interactions with the gut environment, positive and negative human trials, AGA recommendations, and risks in cases of severe illness, immunodeficiency, and central catheters.

Probiotics promise a simple solution in situations where simplicity is rarely found: after taking antibiotics, during bloating, throughout a gastrointestinal infection, or for the sake of a "healthy microflora." On the packaging, it is easy to compare the number of billions of bacteria and the number of species, but these figures say almost nothing about an appropriate indication. The same microorganism might fail to improve the course of acute diarrhea while simultaneously being studied for a completely different task. The decision starts with the question of what exactly we want to change, in which person, and with what preparation.

For this topic, it is especially useful to connect biology with clinical details. Microbes do indeed interact with the intestinal environment; however, the temporary detection of bacteria in stool and a reduction in disease risk are different outcomes. On the following pages, we will break down why a strain is more important than a general name, which trials have yielded useful versus negative answers, and where safety requires a separate discussion. This allows for the discussion of probiotics without a universal prescription and without an equally universal rejection.

## Strain, Dose, and Form: What Exactly Is Called a Probiotic

![Illustration for the section: Strain, Dose, and Form: What Exactly Is Called a Probiotic](https://api.nutrifit.health/api/v2/public/knowledge/files/images/nutrifit-probiotics-20261002-01-strains.png)

A probiotic is a live microorganism that provides a confirmed health benefit when administered in adequate amounts. All three conditions are essential in the definition: viability, an appropriate dose, and a beneficial effect. A culture that grows well in a laboratory does not yet become a remedy for an intestinal disease. As explained in the professional NIH fact sheet, not every product with such a label has proven benefits, and the effects may depend on the specific strain.

A strain is an identifiable lineage within a species of microorganisms. For example, in the name *Lacticaseibacillus rhamnosus* GG, the first two words denote the genus and species, while GG indicates the studied strain; in older publications, its genus is called *Lactobacillus*. This is not a reason to consider any *L. rhamnosus* an equivalent replacement. For clinical discourse, it is useful to retain the full designation from the study, even if a long Latin name seems redundant.

In practice, the name functions as an address: it allows for finding the specific object for which a result has been published. If an article is dedicated to a mixture of two strains, and only two species are listed on the package, the match remains incomplete. If one necessary strain is listed, but it is part of a different mixture, another question arises regarding the reproducibility of the result. A manufacturer may produce a high-quality product, but manufacturing quality and proven efficacy for a selected symptom require different data.

Dose is usually expressed in colony-forming units, or CFU: this is an estimate of the number of viable microorganisms capable of forming colonies under specified conditions. For a live product, the declared viability at the end of the shelf life is essential, not just on the day of production. The CFU count is not a universal scale of therapeutic potency, and a larger dose does not guarantee a greater effect. These labeling features are detailed in the NIH fact sheet.

Imagine two packages: one says "50 billion," and the other says "10 billion" and provides the full strain code. The buyer currently has no basis to prefer the first, because it is unknown whether its composition matches the necessary study. But the second package does not automatically receive an advantage either: indications, regimen, and acceptable safety are still required. Such a sequence of questions protects against choosing based on the largest number.

The form of administration is also part of the intervention description. A fermented milk drink, a powder, and a capsule have different ingredients and conditions of use, so when reading a paper, it is important to record these alongside the strain. One should be especially cautious with research on a pre-made mixture: the result applies to the tested combination and does not prove the contribution of each component individually. This does not imply that a mixture is worse than a single strain; it simply cannot be broken down into arbitrary substitutes.

A fermented product and a probiotic preparation may overlap, but they are different categories. Fermentation describes a method of food production, whereas the status of a probiotic links a specific live microorganism to a health benefit. Regular kefir or fermented vegetables may be enjoyed by a person and fit into their diet without the promise of curing a disease. It is reasonable to purchase them as food based on their nutritional properties and tolerability, while the prescription of a studied strain should be discussed according to the clinical task.

## How Microorganisms Act and Why They Are Not Obliged to Stay Forever

![Illustration for the section: How Microorganisms Act and Why They Are Not Obliged to Stay Forever](https://api.nutrifit.health/api/v2/public/knowledge/files/images/nutrifit-probiotics-20261002-02-colonization.png)

After ingestion, a microorganism encounters a sequence of different environments: the stomach, the small intestine, and the large intestine. Its viability, available nutrients, and interaction with the pre-existing community are essential for any potential effect. Among the mechanisms being studied are competition for resources, the formation of organic acids and other metabolites, and interactions with the epithelium and immune signals. The NIH describes these mechanisms as varying by species and strain, rather than as a mandatory set of properties for any given capsule.

Competition is conveniently illustrated by the example of a nutritional substrate. If an introduced microorganism uses an available compound, there may be less of it for another member of the community. But the result depends on who is present nearby, which substances are supplied by food, and how quickly the environment is renewed. Therefore, suppressing a pathogen in a Petri dish allows for the formulation of a hypothesis, but does not, in itself, predict a reduction in infections in humans.

The same applies to the epithelial barrier—the cell layer that separates the contents of the intestine from the body's tissues. In a cellular model, one can measure permeability or the activity of individual proteins, while in an animal model, one can measure the reaction to experimental damage. Human disease adds medications, age, diet, and varying severity of the process to the equation. The expression "strengthens the intestinal barrier" without specifying the model and clinical outcome leaves too large a part of this chain unexplained.

A human study by Zmora and colleagues used a mixture of 11 strains and examined the intestinal mucosa, not just stool. The work found individual differences in the presence of introduced microbes on the mucosa; detection in stool did not allow for a reliable distinction between these variants. The authors also described temporal and non-uniform changes in the community and gene expression. This mechanistic study helps to understand variability, but does not establish a treatment for a specific disease.

The mucosa and the intestinal contents have different conditions, so a stool sample does not represent the entire organ equally. A microorganism may pass through the intestine, remain viable, and be detected at the exit without colonizing every region. Conversely, one should not reason too quickly in the opposite direction: the absence of permanent colonization does not exclude a temporary effect. Clinical benefit should be assessed by the outcome needed by the person, not by a mandatory requirement to "take root."

For a patient, the promise of colonizing the intestine forever creates an unnecessary goal. If a prescription is aimed at reducing the risk of diarrhea during a limited course of treatment, that period is what matters. If the focus is on maintaining remission of a certain disease, a corresponding regimen and monitoring are needed. Neither of these scenarios requires declaring the intestine an empty space that must be filled with bacteria from a package.

Individual susceptibility to strains does not imply that commercial personalization is ready. To select a preparation based on a microbiota analysis, one must demonstrate that such a choice improves the clinical result compared to a standard approach. The mere existence of differences between people does not prove this. For a healthy person, the promise to "fix" the percentage of bacteria found in an analysis therefore does not replace a clear answer about symptoms, expected benefits, and the reason for the prescription.

## Antibiotics and diarrhea: a beneficial effect depends on the indication

![Illustration for the section: Antibiotics and diarrhea: a beneficial effect depends on the indication](https://api.nutrifit.health/api/v2/public/knowledge/files/images/nutrifit-probiotics-20261002-03-antibiotics.png)

An antibiotic can disrupt microbial functions and cause diarrhea, but not all diarrhea during its use is linked to the same mechanism. Changes in metabolic processing in the intestine, the effect of the drug itself, and *Clostridioides difficile* infection require different clinical approaches. Therefore, it is important in studies to distinguish between general antibiotic-associated diarrhea and a confirmed infection. If these outcomes are combined into a single promise of "gut protection," the patient will receive an inaccurate understanding of the result.

In a trial by Hickson and colleagues, 135 hospitalized patients over 50 years of age were randomized, with a mean age of 74 years. A drink containing *L. casei* DN-114 001, *L. bulgaricus*, and *S. thermophilus* was given at 100 g twice a day during antibiotic therapy and for one week thereafter. Among the 113 individuals with available follow-up, diarrhea occurred in 7 of 57 (12%) in the drink group and in 19 of 56 (34%) in the control group. The absolute difference was approximately 22 percentage points.

This is a notable result; however, the study was small, and follow-up was not completed for approximately 16% of participants. People with severe, life-threatening conditions and immunodeficiency were excluded, so the safety for such patients was not established. The high frequency of diarrhea in the control group also limits the transfer of the obtained absolute benefit to another hospital or outpatient practice. The result applies to the tested drink and regimen, not to all yogurts.

The large PLACIDE trial involved 2,981 hospitalized patients aged 65 years or older who were receiving antibiotics. A mixture of lactobacilli and bifidobacteria was administered in capsules at a dose of 6 × 10¹⁰ microorganisms per day for 21 days; the primary outcome analysis included 2,941 individuals. Antibiotic-associated diarrhea occurred in 10.8% of the mixture group and 10.4% in the placebo group: a relative risk of 1.04, 95% confidence interval 0.84–1.28. For *C. difficile*-associated diarrhea, the rates were 0.8% and 1.2%, also showing no convincing difference.

Conflicting results should not be explained by a single convenient reason that these studies did not directly test. The preparation, patient selection, baseline risk, and care settings differed; therefore, there is no simple head-to-head comparison of doses between trials. PLACIDE demonstrates that a large number of microorganisms and multi-strain composition do not, in themselves, ensure prevention. A small positive trial, in turn, provides a basis for studying a specific regimen, but it does not override negative data.

The 2020 AGA Guideline conditionally suggests specific preparations for the prevention of *C. difficile* infection in adults and children receiving antibiotics. Among the options are *S. boulardii* and a combination of *L. acidophilus* CL1285 with *L. casei* LBC80R; this is not a recommendation for any mixture for any type of diarrhea. For existing infection, the AGA limits the use of probiotics to the framework of clinical trials. Prevention and treatment cannot be interchanged here.

When discussing benefits, it is worth asking for absolute numbers alongside relative ones. A purely theoretical example: with a baseline risk of 2% and a relative risk of 0.5, the expected difference is one percentage point, whereas with a baseline risk of 20%, it is ten. This is an illustration of arithmetic, not a forecast for the listed preparations. It explains why the same relative effect can have different implications for two patients and why the decision involves baseline risk, cost, and safety.

## Intestinal diseases: recommendations apply to specific scenarios

![Illustration for the section: Intestinal diseases: recommendations apply to specific scenarios](https://api.nutrifit.health/api/v2/public/knowledge/files/images/nutrifit-probiotics-20261002-04-conditions.png)

Irritable bowel syndrome, ulcerative colitis, and Crohn’s disease may be accompanied by similar complaints, but they are different conditions. When choosing an intervention, it is insufficient to say that the microbiota is involved in all of them: a diagnosis, activity of the process, and the desired outcome are required. Reducing bloating, maintaining remission, and healing inflamed mucosa are also not interchangeable. Therefore, a broad label of "for the gut" does not help determine a preparation's place in treatment.

In the AGA probiotic guideline for symptomatic irritable bowel syndrome, Crohn’s disease, and ulcerative colitis, use is limited to clinical trials. Such a position reflects insufficient confidence in prescribing for these tasks and does not mean that every individual study is necessarily negative. It also does not confirm the benefit of a product selected by a general list of bacteria. For a patient with an established disease, it is important to discuss a supplement in the context of primary treatment.

A special scenario is pouchitis, an inflammation of the reservoir formed from the small intestine after certain surgeries for ulcerative colitis. The reservoir is created to maintain the route of intestinal content evacuation after the removal of the colon, and the conditions within it differ from normal anatomy. This example cannot be extrapolated to a person without such surgery. Here, the rationale for the prescription is linked to a specific postoperative condition, not to universal "flora restoration."

A later AGA guideline on pouchitis, published in the journal in 2024, suggests probiotics for the prevention of relapse after a response to antibiotics. It does not provide a recommendation for or against probiotics for primary prevention of pouchitis or the treatment of its rare active episodes. In the evidence base for relapse prevention, a specific multi-component formula was studied, not arbitrary mixtures. For the patient, these distinctions define the moment when a supplement is even discussed.

In the full text of the guideline, three randomized trials of relapse prevention with 6–12 months of follow-up showed a combined relative risk of 0.17, with an interval of 0.09–0.34. The authors rated the confidence in the evidence as low, despite the large relative effect. Such a result should be kept within context: small studies, response to antibiotics, and a specific formula. It does not turn into permission to replace treatment for active inflammation with any capsule from a pharmacy.

For a specialist, it is useful to distinguish between the onset of remission and its maintenance. If treatment is carried out first, after which symptoms subside, the subsequent reduction in relapses addresses the question of maintaining the result. If a person starts a medication during active disease, this is a different task, even with the same diagnosis. Likewise, a positive response to treatment in one group does not establish the prevention of a first episode in another.

A reader who sees a familiar disease name in an advertisement should clarify the entire prescription scenario. How the diagnosis was determined, what was received concurrently, what the composition used was, and how long the effect was observed are practical questions, not formalities. If the available packaging does not correspond to the description of the studied product, confidence in transferring the result decreases. In the absence of a response, it is more useful to return to the doctor with these details than to independently increase the dose or the number of strains.

## Acute diarrhea in children: why the expected improvement may not appear

![Illustration for the section: Acute diarrhea in children: why the expected improvement may not appear](https://api.nutrifit.health/api/v2/public/knowledge/files/images/nutrifit-probiotics-20261002-05-child.png)

Intestinal infection seems like a natural task for a product with microorganisms. However, in this situation, it is not only the pathogen and the microbial community that are important, but also fluid loss, the child’s age, and the course of the disease. Reducing diarrhea by a few hours and preventing a severe condition are different goals. The supplement should be evaluated as an additional intervention with its own outcomes, without allowing its choice to overshadow necessary care.

In the study by Schnadower and colleagues, 971 children aged 3 months to 4 years with acute gastroenteritis received either LGG or a placebo. The strain was administered at 1 × 10¹⁰ CFU twice daily for five days. A moderate or severe course according to the modified Vesikari scale was observed in 11.8% and 12.6%, respectively; the published relative risk was 0.96 with a 95% confidence interval of 0.68–1.35. The median duration of diarrhea was 49.7 and 50.9 hours, with no statistically significant difference.

This trial answers the question about a specific strain under specific conditions of pediatric emergency care in the USA. It does not establish the same result for all microorganisms, countries, and causes of diarrhea. But it significantly limits the promise that a familiar probiotic will necessarily accelerate a child’s recovery. A high dose here did not become the basis for a clinical advantage over the placebo.

The AGA, in its 2020 clinical guidance, suggests not using probiotics for acute infectious gastroenteritis in children. When discussing another recommendation, it is important to clarify its region, strain, and confidence in the effect, rather than combining positions into a general "doctors advise." A family needs an answer for a real situation, age, and available treatment. The name of a product category does not replace these conditions.

A negative trial is especially useful for evaluating everyday experience. A child may recover shortly after starting a supplement, and this is naturally perceived as its effect. But without a comparison group, it is unknown how long recovery would have taken with the same care without the preparation. Therefore, personal observation is significant for describing tolerability and the course of the disease, but it does not allow for a separate measurement of the therapeutic effect.

In this situation, it is dangerous to delay seeking help for the sake of choosing the next brand. If a child drinks poorly, becomes noticeably lethargic, urinates rarely, or if blood appears in the stool, the issue goes beyond the choice of a supplement. A probiotic does not replace water and electrolytes lost with liquid stool. Discussing nutrition and rehydration with a medical specialist has independent significance regardless of the decision regarding microorganisms.

The same limits of transfer apply to promises to "support immunity." Even if the interaction of a strain with immune signals has been studied, it does not follow that this prevents all infections or provides benefit in any case of diarrhea. Such a promise would require separate human trials with predefined outcomes. A reasonable request to a manufacturer sounds specific: which disease or symptom, in which group of people, and over what time did this specific composition change.

## Safety: live microorganisms require patient assessment

![Illustration for the section: Safety: live microorganisms require patient assessment](https://api.nutrifit.health/api/v2/public/knowledge/files/images/nutrifit-probiotics-20261002-06-safety.png)

A healthy person and a patient in the intensive care unit have different risk conditions. Immune defense, intestinal integrity, tissue blood supply, and the presence of vascular devices affect the consequences of contact with live microbes. Therefore, the tolerability of a preparation in an outpatient study does not establish its safety in intensive care. Before prescribing, it is especially important to ask about severe illness, immunosuppression, and central venous catheters, rather than limiting the inquiry to food allergies.

The most illustrative example is PROPATRIA, a randomized trial in predicted severe acute pancreatitis. The study enrolled 298 patients, and a multi-strain preparation was administered enterally twice daily for 28 days. Infectious complications did not decrease: 30% versus 28%; mortality was 16% versus 6%, with a relative risk of 2.53 and a confidence interval of 1.22–5.25. Bowel ischemia was detected in nine patients receiving the preparation and in none of the control group patients.

These results pertain to severe pancreatitis and the specific intervention tested. They do not provide grounds to declare the same mortality for the routine consumption of probiotics by healthy adults. However, they show that a biologically attractive idea of preventing infection may prove harmful in a vulnerable population. Explaining the benefit through a presumed effect on the barrier does not allow one to assume safety in advance for use in cases of impaired blood supply and severe tissue damage.

Another type of data was obtained in a study by Yelin and colleagues at a children's hospital. Genomic comparison linked bacteria from a probiotic preparation to six independent episodes of bloodstream infection in intensive care patients. The precise route of entry of the microorganism into the blood remained unclear: translocation through the intestinal wall and contamination of a central catheter were discussed. This is an observational study with molecular confirmation of the link, rather than a randomized assessment of risk for all users.

*S. boulardii* is a yeast microorganism, so for it, the risk of fungemia, the presence of fungi in the blood, is significant. In a Finnish study by Rannikko and colleagues covering 2009–2018, 46 patients with *Saccharomyces* fungemia were identified; at least 20, or 43%, had used *S. boulardii*. Compared to the control group, the odds ratio for using the preparation was 14, with a confidence interval of 4–44. The authors emphasize the limitations of use in the presence of catheters, immunodeficiency, critical illness, and impaired integrity of the gastrointestinal tract.

The figure of 43% here cannot be read as the probability of a complication in a person taking the preparation. The researchers started with identified cases of infection, not with all probiotic consumers, so the denominator for such a calculation is missing. The odds ratio also does not mean a fourteenfold risk for any healthy buyer. The observation shows a clinically significant signal and helps to determine the conditions for caution while maintaining the correct scale of the conclusion.

A practical risk assessment includes not only the name of the microorganism but also the way the product is handled. For a person with a catheter, conditions of preparation and administration are important, because potential contamination of the device cannot be ruled out by good tolerance of food alone. With immunosuppression, the choice of a living preparation requires the involvement of the medical team, who are aware of the severity of the condition and the therapy. If a patient is hospitalized, a supplement brought from home must also be part of the list of agents known to the staff.

Childhood, pregnancy, and chronic illness do not combine into one "safe for everyone" category. Prescription requires composition and data relevant to the appropriate group; this especially applies to newborns and people with severe comorbidities. At the same time, one should not attribute every temporary complaint to a dangerous infection: its probability depends on the situation. The goal of the assessment is to recognize specific vulnerability and ensure timely medical care, not to create fear of all fermented foods.

## How to choose a preparation and determine if further intake is needed

![Illustration for the section: How to choose a preparation and determine if further intake is needed](https://api.nutrifit.health/api/v2/public/knowledge/files/images/nutrifit-probiotics-20261002-07-choice.png)

One should start by describing the task in plain language. "I want fewer episodes of diarrhea while on antibiotics" poses a different question than "I want to improve my microbiota," and "I want to prevent a pouchitis relapse" requires a known diagnosis and prior treatment. The clearer the goal, the easier it is to find the relevant study and discuss the result. If the goal cannot be formulated, purchasing based on the number of strains is unlikely to resolve this uncertainty.

Then, it is useful to write down the full name of the preparation, the strains, the daily dose, the form, and the expected duration. During a consultation, this allows for discussing a specific agent rather than a category from an advertisement. For a multi-component product, the entire composition should be compared, including ingredients that may affect tolerance. If the tested variant is unavailable, the substitution becomes a separate decision, and it cannot be justified solely by a similar species name.

Preventive and symptomatic courses require different methods of assessment. When treating a symptom, one can predefine its frequency, severity, and impact on daily life in order to subsequently compare the condition under identical circumstances. In prevention, the absence of an event in one person does not demonstrate that the drug specifically prevented it. This distinction helps in discussing the continuation of a course without requiring evidence of microbiome changes in lab tests.

A simple diary is useful if its goal is clear and it does not turn into constant monitoring of every sensation. For example, to discuss gastrointestinal complaints, agreed-upon indicators of stool frequency, pain, and tolerability, as well as a list of concurrent treatment changes, are sufficient. A predetermined review date corresponding to the clinical scenario is essential. The universal term "take for a month for everyone" does not follow from a five-day gastroenteritis study or from long-term observation of pouchitis recurrence.

Storage conditions deserve the same attention as the dosage. It is necessary to follow the instructions for a specific product, take the expiration date into account, and distinguish between the CFU count at the time of manufacture and at the end of the shelf life. NIH draws attention specifically to viability at the end of the shelf life. The requirement to store a product in a refrigerator or at room temperature is determined by its characteristics, so a habit suitable for one product should not be automatically applied to another.

Combining with medications cannot be reduced to a single schedule either. When choosing an interval with an antibiotic, the instructions, the specific drug, and its composition matter; for a yeast-based product, antifungal agents are discussed separately. Arbitrary spacing of doses does not turn an unsuitable strain into one with proven efficacy. The question of a regimen makes sense after a decision regarding the indication has been made, and in complex therapy, it is better to discuss this with a doctor or pharmacist using a full list of medications.

If a supplement contains inulin or other fermentable ingredients, changes in gas production cannot be automatically attributed to the microorganisms themselves. Such a composition creates an additional question of what exactly is being poorly tolerated and which part of the product was studied. Unpleasant sensations are not proof of "cleansing" or a necessary stage of action. In case of worsening, one should reconsider the intake and the clinical situation, rather than increasing the dose for the sake of assumed adaptation.

Cost becomes especially important when the goal is uncertain and intake is long-term. It is useful to discuss in advance what expected result justifies the expenses, how likely this result is, and what will be the basis for discontinuing the course. For a person without symptoms, the question of a permanent supplement differs from a specific medical prescription. The lack of suitable data leaves the choice uncertain but does not create an obligation to regularly purchase the product "just in case."

Ultimately, a competent prescription can be presented in one coherent explanation: a specific composition is used for a specific task in a suitable patient, in a studied regimen, and with consideration of risk. All parts of this explanation are needed simultaneously. Microbiology helps to understand the possible action, human trials show the result, and the clinical context determines applicability. Such an approach makes a probiotic a discussable intervention with boundaries, instead of an undefined promise to improve overall health.

## FAQ

### Should everyone take a probiotic after antibiotics?

Universal prescription is not supported by current trials. The result depends on the specific product, clinical task, and baseline risk; in the large PLACIDE trial, the studied mixture did not reduce diarrhea. Decisions should be discussed for a specific composition and patient, distinguishing between the prevention of general diarrhea and C. difficile infection.

### How do I know if a product matches a study?

You need to compare full strain designations, the entire composition of the mixture, the daily dose, form, and duration. Matching only the species name is insufficient. Then, verify if the product was studied in people with the same condition and comparable treatment conditions.

### Is more billions of CFU better?

CFU count is not a universal scale of efficacy. A larger dose does not compensate for the lack of a suitable strain or indication. It is also important to check the expiration date, storage conditions, and the number of viable microorganisms at the end of the shelf life on the packaging.

### Should a probiotic permanently colonize the gut?

Permanent colonization is not an essential goal of supplementation. Human mechanistic studies have shown individual differences in mucosal interaction, and detection in stool does not provide a complete picture of this process. Clinical effect is evaluated by the desired outcome, not by the promise of permanent colonization.

### Can I replace a studied supplement with regular kefir?

Kefir can be chosen as a food product based on its composition and tolerability. However, fermentation itself does not confirm the effect of a specific probiotic strain for a disease. Extrapolating the result of a capsule or a specific drink to any kefir requires separate data.

### Does LGG help with every acute diarrhea in a child?

In a large trial in US pediatric emergency departments, a five-day course of LGG did not improve the course of gastroenteritis compared to a placebo. This result applies to the specified strain and conditions, but limits the promise of mandatory improvement. Choosing a supplement should not delay assessment and care for fluid loss.

### Who specifically needs to discuss safety with a doctor?

Patients in critical condition, those with immunosuppression, a central venous catheter, or compromised gut integrity. For S. boulardii, cases of fungemia have been described, and for bacterial products, bloodstream infections have been reported in vulnerable clinical groups. Tolerance results in healthy adults do not establish safety for such patients.

### How long should I take a probiotic?

Duration is determined by the indication and the studied regimen of the specific product. A five-day course for gastroenteritis, intake during antibiotics, and prevention of pouchitis recurrence answer different questions. Before starting, it is useful to agree on the expected outcome and a date to review the necessity of further intake.

## Sources

- [NIH: пробиотики — справка для медицинских специалистов](https://ods.od.nih.gov/factsheets/Probiotics-HealthProfessional/)
- [AGA, 2020: роль пробиотиков в ведении желудочно-кишечных заболеваний](https://gastro.org/clinical-guidance/role-of-probiotics-in-the-management-of-gastrointestinal-disorders/)
- [AGA, 2024: клиническое руководство по паучиту и воспалительным заболеваниям кишечного резервуара](https://pmc.ncbi.nlm.nih.gov/articles/PMC11163976/)
- [Zmora и соавторы, 2018: индивидуальная устойчивость слизистой кишечника к колонизации пробиотиками](https://pubmed.ncbi.nlm.nih.gov/30193112/)
- [Hickson и соавторы, 2007: пробиотический напиток для профилактики диареи на фоне антибиотиков](https://www.bmj.com/content/335/7610/80)
- [Allen и соавторы, 2013: PLACIDE — профилактика антибиотик-ассоциированной диареи у пожилых госпитализированных пациентов](https://pubmed.ncbi.nlm.nih.gov/23932219/)
- [Schnadower и соавторы, 2018: Lactobacillus rhamnosus GG против плацебо при остром гастроэнтерите у детей](https://pubmed.ncbi.nlm.nih.gov/30462938/)
- [Besselink и соавторы, 2008: PROPATRIA — пробиотическая профилактика при прогнозируемом тяжёлом остром панкреатите](https://pubmed.ncbi.nlm.nih.gov/18279948/)
- [Yelin и соавторы, 2019: геномные и эпидемиологические данные о переходе бактерий из пробиотического препарата в кровь пациентов интенсивной терапии](https://pmc.ncbi.nlm.nih.gov/articles/PMC6980696/)
- [Rannikko и соавторы, 2021: фунгемия и другие грибковые инфекции, связанные с добавками Saccharomyces boulardii](https://wwwnc.cdc.gov/eid/article/27/8/21-0018_article)
- [American Gastroenterological Association. Management of pouchitis and inflammatory pouch disorders](https://gastro.org/clinical-guidance/management-of-pouchitis-and-inflammatory-pouch-disorders/)